Sara
Villar Fernández
Colaboradora Clínica
Publications (35) Sara Villar Fernández publications
2026
-
HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study
eClinicalMedicine, Vol. 91
-
Haemostatic changes during CART cell therapy and risk of complications
Cancer Immunology, Immunotherapy, Vol. 75, Núm. 4
-
Outcomes of Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis in Myelodysplastic Syndromes: A Multicenter Study Conducted on Behalf of GETH-TC
Transplantation and Cellular Therapy
-
Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH-TC study
British Journal of Haematology
2025
-
Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
Blood Cancer Journal, Vol. 15, Núm. 1
-
Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study
Transplant Infectious Disease, Vol. 27, Núm. 5
-
Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC
Frontiers in Immunology, Vol. 16
-
Early cardiac events after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. subanalysis exploring cardiac toxicity conducted on behalf of GETH-TC
Frontiers in Immunology, Vol. 16
-
Emerging Risk of Campylobacter spp. Infection Associated With Anti-BCMA and Anti-GPRC5D Bispecific Antibodies
Open Forum Infectious Diseases, Vol. 12, Núm. 11
-
Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care
Frontiers in Immunology, Vol. 15
-
Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study
British Journal of Haematology, Vol. 207, Núm. 4, pp. 1504-1516
-
Progressive Multifocal Leukoencephalopathy (PML) after hematopoietic cell transplantation (HCT): a retrospective study of Infectious Diseases Working Party (IDWP) of the EBMT
Bone Marrow Transplantation
-
Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis
Cancer Immunology, Immunotherapy, Vol. 74, Núm. 6
-
Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation
Cancers, Vol. 17, Núm. 19
-
The role of stem cell transplantation in the modern management of multiple myeloma
Current Opinion in Hematology
2024
-
Cardiac events after allo-HCT in patients with acute myeloid leukemia
Blood Advances, Vol. 8, Núm. 21, pp. 5497-5509
-
Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC
Bone Marrow Transplantation, Vol. 59, Núm. 12, pp. 1694-1703
-
Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia
Blood Neoplasia, Vol. 1, Núm. 3
-
Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
Bone Marrow Transplantation, Vol. 59, Núm. 7, pp. 965-973
2023
-
Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia
JCI Insight, Vol. 8, Núm. 2